Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.58 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.42 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.42 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.42 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.42 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.42 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.42 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.42 |
| ▸ | AIMP2 | Q13155 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15865330 | 1.00 | CA2 (0.58) | CA2DRD2PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL1043944 | 0.93 | CA2 (0.51) | CA2DRD2AIMP2ALOX5HTR1A | |
| SCHEMBL29481769 | 0.93 | CA2 (0.51) | CA2DRD2AIMP2ALOX5HTR1A | |
| SCHEMBL29444757 | 0.93 | CA2 (0.51) | CA2DRD2AIMP2ALOX5HTR1A | |
| SCHEMBL1043824 | 0.93 | CA2 (0.51) | CA2DRD2AIMP2ALOX5HTR1A | |
| SCHEMBL15865011 | 0.83 | CA2 (0.58) | CA2DRD2AIMP2ALOX5HTR1A | |
| SCHEMBL15865008 | 0.83 | CA2 (0.58) | CA2DRD2AIMP2ALOX5HTR1A | |
| SCHEMBL15864966 | 0.81 | CA2 (0.38) | CA2DRD2PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL1044700 | 0.81 | CA2 (0.38) | CA2DRD2PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL5917931 | 0.80 | CA2 (0.58) | CA2PRKAB2PRKAG1PRKAA2PRKAA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2941427-B1 | NOVEL BENZODIOXANE-PIPERIDINE DERIVATIVES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | PF MEDICAMENT (FR) | 2016-11-09 | — | — | EP | disclosed |
| EP-2941427-B1 | NOVEL BENZODIOXANE-PIPERIDINE DERIVATIVES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | PF MEDICAMENT (FR) | 2016-11-09 | — | — | EP | disclosed |
| US-20150336943-A1 | NOVEL BENZODIOXANE-PIPERIDINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS FOR TREATING NEUROPSYCHIATRIC DISORDERS | PIERRE FABRE MEDICAMENT (FR) | 2015-11-26 | — | — | US | disclosed |
| US-20150336943-A1 | NOVEL BENZODIOXANE-PIPERIDINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS FOR TREATING NEUROPSYCHIATRIC DISORDERS | PIERRE FABRE MEDICAMENT (FR) | 2015-11-26 | — | — | US | disclosed |
| US-20150336943-A1 | NOVEL BENZODIOXANE-PIPERIDINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS FOR TREATING NEUROPSYCHIATRIC DISORDERS | PIERRE FABRE MEDICAMENT (FR) | 2015-11-26 | — | — | US | disclosed |
| EP-2941427-A1 | NOVEL BENZODIOXANE-PIPERIDINE DERIVATIVES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | Pierre Fabre Médicament (FR) | 2015-11-11 | — | — | EP | disclosed |
| WO-2014106660-A1 | NOVEL BENZODIOXANE-PIPERIDINE DERIVATIVES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | PIERRE FABRE MEDICAMENT (FR) | 2014-07-10 | — | — | WO | disclosed |
| WO-2014106660-A1 | NOVEL BENZODIOXANE-PIPERIDINE DERIVATIVES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | PIERRE FABRE MEDICAMENT (FR) | 2014-07-10 | — | — | WO | disclosed |
| US-5962465-A | BRAIN DISORDERS; PSYCHOLOGICAL DISORDERS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336943-A1 | NOVEL BENZODIOXANE-PIPERIDINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS FOR TREATING NEUROPSYCHIATRIC DISORDERS | HCRTR1, HCRTR2, OXSR1 | CA2 4017/4885DRD2 22/4885PRKAB2 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.